In Romania, reimbursed standard treatment for HR-positive HER2-negative advanced breast cancer tumors is aligned with European Guidelines [13], which recommends a preferred first-line as CDK4/6 inhibitor plus ET. The gene discussed is CDK4; the disease is breast carcinoma.